-

nihao guest [ sign in / register ]
2026-2-4 13:14:35


Zhang YF, Xu R, Luo J, Ma Y, Xiao G, Liu Y. Identification of Mannose-Capped-Arabinomannan 101-mer as a Potential Influenza Virus Vaccine Adjuvant. Adv Sci (Weinh). 2026 Feb 3:e19843
submited by kickingbird at Feb, 4, 2026 8:53 AM from Adv Sci (Weinh). 2026 Feb 3:e19843

Many natural bacterial components as adjuvants can activate the host immune system, but the excessive toxicity and structure-identification challenge limit their applications and structure-activity relationship studies. Herein, we report the role of a series of chemically synthesized mannose-capped arabinomannan motifs from Mycobacterium tuberculosis cell wall, including 18-mer, 19-mer, 27-mer, and 101-mer in regulating host immunity. As an influenza vaccine adjuvant, 101-mer induced significantly enhanced anti-influenza antibody response and immune protection compared with other arabinomannan motifs. 101-mer elicited robust immunoenhancement while exhibiting a favorable tolerability profile, as it did not trigger any observable physiological toxicity or inflammatory reactions in various organs. Mechanistically, we found 101-mer may serve as a Dectin-2 agonist to activate host immunity through Syk/NF-κB signaling. This study provided a new oligosaccharide candidate that can satisfy the required "efficacy-safety" balance for clinical adjuvant development.

See Also:

Latest articles in those days:

[Go Top]    [Close Window]

Related Pages:
Learn about the flu news, articles, events and more
Subscribe to the weekly F.I.C newsletter!


  

Site map  |   Contact us  |  Term of use  |  FAQs |  粤ICP备10094839号-1
Copyright ©www.flu.org.cn. 2004-2026. All Rights Reserved. Powered by FIC 4.0.1
  Email:webmaster@flu.org.cn